I. MODIFIED AGREEMENTS | |||
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Change from |
Terms/Details (Date) |
| | |||
Discovery |
Theracos Inc.* |
Extended medicinal |
Financial terms of the milestone-based collaboration were not disclosed (10/22) |
Epimmune |
Genencor International |
Extended collaboration focused on the development of vaccines to treat or prevent hepatitis C, hepatitis B and human papillomaviruses |
The agreement began in July 2001 and is extended through September 2004; Genencor fully funds Epimmune's R&D expenses and will pay Epimmune royalties on sales of any products that result; Genencor also would make milestone payments to Epimmune (10/21) |
Gene Logic |
IDEC Pharmaceuticals Corp. (IDPH) |
Extended subscription agreement for the GeneExpress Oncology DataSuite for use in IDEC's drug discovery and development efforts focused on cancer therapies |
IDEC's researchers will continue to use the suite's genomic and clinical information on normal and diseased human tissues to support their internal genomics-driven target identification and validation initiatives (10/7) |
XOMA Ltd. |
Diagnostic Products Corp. (NYSE:DP) |
Expanded agreement to give Diagnostic Products exclusive, worldwide rights to use XOMA technology to develop non-automated, point-of-care, single-sample products |
Additional financial and other terms were not disclosed (10/8) |
II. TERMINATED AGREEMENTS | |||
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Change from |
Terms/Details (Date) |
| | |||
Seattle |
Genentech Inc. |
Terminated agreement for the development of SGN-14 |
Seattle Genetics regains all rights to the anti-CD40 monoclonal antibody, and will continue development in hematological malignancies (10/8) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange | |||
